Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $72.00

Halozyme Therapeutics (NASDAQ:HALO) had its target price increased by HC Wainwright from $70.00 to $72.00 in a report published on Wednesday,Benzinga reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock.

Other research analysts have also issued reports about the stock. Wells Fargo & Company decreased their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. JMP Securities raised their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research note on Friday, November 1st. Finally, Piper Sandler raised their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a report on Friday, January 10th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $62.78.

Halozyme Therapeutics Trading Up 0.5 %

HALO opened at $57.75 on Wednesday. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. The company’s 50 day simple moving average is $53.46 and its two-hundred day simple moving average is $54.62. Halozyme Therapeutics has a 1-year low of $37.73 and a 1-year high of $65.53. The firm has a market capitalization of $7.11 billion, a price-to-earnings ratio of 16.84, a price-to-earnings-growth ratio of 0.44 and a beta of 1.25.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping analysts’ consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The business had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. Analysts expect that Halozyme Therapeutics will post 4.72 EPS for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 10,000 shares of the business’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the sale, the director now directly owns 43,611 shares of the company’s stock, valued at $2,180,986.11. The trade was a 18.65 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. GF Fund Management CO. LTD. purchased a new stake in Halozyme Therapeutics in the fourth quarter valued at $128,000. Novem Group purchased a new stake in Halozyme Therapeutics in the fourth quarter valued at $841,000. Voloridge Investment Management LLC purchased a new stake in Halozyme Therapeutics in the fourth quarter valued at $876,000. Two Sigma Advisers LP purchased a new stake in Halozyme Therapeutics in the fourth quarter valued at $282,000. Finally, Two Sigma Investments LP lifted its position in Halozyme Therapeutics by 403.0% in the fourth quarter. Two Sigma Investments LP now owns 247,030 shares of the biopharmaceutical company’s stock valued at $11,811,000 after acquiring an additional 197,918 shares during the last quarter. 97.79% of the stock is owned by hedge funds and other institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.